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A greater number of adults with CV events were identified in the PFO
group (50) vs control group (34). p < 0.07. The proportion of adults with
The relative odds associated with a 80 mg/dl (1 STD) increase of fibrino-
gen (adjusted in multiple logistic regression for the above parameters) was
1.47 (90% CI1.22-1.77). Conclusion: Fibrinogen emerged as an independent








Age PFO Stroke (PFO group) Stroke (Control group)
(yrs) NON CRYP NON CRYP
0-1 520 (26%) 1 a a a
1-18 88(2%) a a 1 a
18-50 127(1%) 9 13 1 a
>50 309(1%) 23 5 28 5
Rate
embolism, non-fatal myocardial infarction or vascular death. An interim anal-
ysis carried out on the first 582 patients irrespectively from treatment groups
showed an overall stroke rate (2.9%) and a frequency of primary end-points
(7.4%) very similar to those observed in the anticoagulant arm of a recently
published study (European Atrial Fibrillation Trial). The final results of the SIFA
trial should help to clarify the role of antiplatelet drugs in the prevention of
stroke in NVAF patients.
8:45
1735-21 Fibrinogen is an Independent Predictor of Ischemic
StrokerrlA in Patients with Coronary Heart Disease
David Tanne, Uri Goldbourt, Michal Benderly, Valentina Boyko,
Henrietta Reicher-Reiss, Solomon Behar, Bezafibrate Infarction Prevention (SIP)
Study Group. Neufeld Cardiac Research Institute, Tel Hashomer, fsrael
In order to determine the association between baseline fibrinogen levels and
subsequent development of ischemic stroke or transient ischemic attack
(TIA) we followed prospectively patients (pts) with chronic ischemic heart
disease (CIHD) included in the BIP study for new cerebrovascular events.
This study includes 31 22 pts aged 45-74 with TC 180-250, triglycerides,
:,:300 and HDL :,:45 mg/dl without a prior stroke, randomized to either 400
mg/dl Bezalip Retard or placebo. The annual rate of cerebrovascular events
among these pts was 0.8% (69 pts - 12 TIA, 57 stroke). Fifty of the strokes
were cerebral infarction, 5 of uncertain type (probably ischemic) and 2 in-
tracerebral hemorrhage. Pts developing ischemic strokelTlA (67 pts) were
older than those without this complication (mean age 61.5 vs. 59.7 years).
had higher systolic blood pressure measurements (138 ± 21 vs. 133 ± 18
mmHg) and higher rate of severe (class 2-4) anginal syndrome (36% vs.
23%). History of diabetes (24% vs. 9%), peripheral vascular disease (10%
vs. 3%) and current smoking (19% vs. 11 %) were more prevalent among pts
with ischemic strokelTlA than among counterparts without this complication
(p < 0.05). Fibrinogen levels were significantly higher in pts subsequently de-
veloping ischemic strokelTlA (388 ± 70 vs. 349 ± 73 mg/dl, p < 0.0001). Age
adjusted ischemic strokelTlA rates/100 person years in fibrinogen quintiles
were as follows.
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1735-31 A Study of 1044 Consecutive Patients with Patent
Foramen Ovale: Association with Cryptogenic
Cerebrovascular Events in Adults
Sumita D. Paul, Mary Etta King, Michael H. Picard, Stella V. Brili, Peter Lang, John
B. Newell, Richard R. Liberthson, Ariane J. Marelli. Massachusetts General Hospital,
Harvard Medical School, Boston, MA
The natural history of patent foramen ovale (PFO) in association with cere-
brovascular (CV) events has not been described. With the development of
devices for non-surgical closure of atrial septal defect, it is possible that
the risk of PFO closure may be minimal. However, the potential benefit of
PFO closure remains unknown and difficult to assess due lack of adequate
data.
To determine the prevalence of PFO and its association with cryptogenic
(CRYP) and non-cryptogenic (NON) stroke, we examined the database of
37,940 consecutive pts who underwent echocardiography between 1984
to 1994, to identify pts diagnosed with PFO (n = 1044) and designed an
age-matched nested case-control study with 2088 pts to determine the as-
sociation of CV events to PFO. All CV events were confirmed by review of
medical records. NON stroke was defined: cardiogenic, atherosclerotic, la-
cunar, arteritis, aneurysm, hematoma. CRYP stroke was diagnosed by ex-
clusion when the event could not be ascribed to causes in the NON group.
Results: The age distribution is given below:
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Three-dimensional (3-D) vessel reconstruction using intravascular ultrasound
(IVUS) is limited by the lack of information on the real vessel curvatures and
the orientation of the IVUS catheter.
To overcome these limitations a method was developed using data ob-
tained from ANGiography and intravascular UltraSound (ANGUS). This tech-
nique provides real spatial geometry and orientation of coronary lumen and
plaque. The artery is studied by IVUS during a pull-back (PB) of the IVUS
catheter at a speed of 1 mm/s. Start and end of the PB are recorded by bi-
plane fluoroscopy (BF) and finally biplane coronary angiography (BA) is per-
formed without changes in geometrical X-ray settings.
Using a new computer program the contours of the lumen-plaque and
plaque-adventit;a boundaries are semi-automatically detected at 0.5 mm
intervals. BF allows geometrical reconstruction of the catheter trajectory,
which is the path of the IVUS transducer during PB. Combined use of the
IVUS data, the catheter trajectory and the lumen contours in the BA pro-
vides a unique 3-D reconstruction of coronary arteries without any evidence
of an additional unknown geometric factor. Studying the trajectory in a ves-
sel phantom of known dimensions a high accuracy was found (distance be-
tween reconstructed and real trajectory at any point <2 mm). First appli-
cation in a human right coronary artery in-vivo (length: 75 mm) showed a
difference of 2% between the length of the reconstructed trajectory and the
PB distance. Checking the locations of the origin of side-branches in the 3-D
reconstruction and BA differences of less than 2 mm were found. Location
and shape of stenoses in simulated projections of the reconstructed lumen
matched well with BA. However, at the site of a previous PTCA luminal hazi-
ness in angiography and dissection observed by IVUS may slightly reduce
the accuracy of this technique.
Thus combining ANGiography and intravascular UltraSound (ANGUS) is
promising and provides a unique reconstruction of 3-D coronary geometry.
Camelis J. Slager, Martin Laban, Clemens von Birgelen, Rob Krams, Jan
A.F. Oomen, Ad den Boer, Li Wenguang, Pim J. de Feyter, Patrick W Serruys. Jos
R.T.C. Roeland!. Thoraxcenter, Erasmus University Rotterdam, The Netherlands
ANGUS: A New Approach to Three-dimensional
Reconstruction of Geometry and Orientation of
Coronary Lumen and Plaque by Combined Use of
Coronary Angiography and IVUS
3, 28%). In all cases except in 1, in which balloon PTCA was used after RF,
RF was used alone. Pressure was maintained at the lowest level to assure
full balloon expansion, temperature was set to 55'C. After RF lumen area
increased from 2.3 ± 1.1 mm2 to 7.19 ± 1.8 mm2 (p < 0.001). After RF in 7
lesions (63%) plaque rupture was observed (1 partial; 2 extending to media;
4 with accompanying dissection). The main mechanism for the increase in
lumen area was: a) Plaque rupture and/or dissection n = 6 (54%); b) Plaque
compression n = 4 (36%); c) "Total artery" dilation n = 1 (9%).
In conclusion, the mechanism of luminal enlargement after RF, as viewed
with ICUS, was similar to that reported with conventional PTCA, with plaque
rupture/dissection followed by plaque compression being the main mecha-
nisms.
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Gabriella Cataldo, SIFA Study Group. Institute of Neurology, University of Rome "La
Sapienza~ Italy
The effect of oral anticoagulation for primary and secondary prevention of
stroke in patients with non-valvular atrial fibrillation (NVAF) has been clearly
shown in several studies. Still uncertain is the role of antiplatelet agents. The
SIFA is a multicenter open randomized trial which aims to compare the effi-
cacy and safety of an oral anticoagulant treatment (Wartarin to obtain an INR
of 2.0-3.5) with an antiplatelet drug (Indobufen, a reversible cyclooxygenase
inhibitor, 100-200 mg bid) in patients with NVAF and a recent (:,:14 days)
transient ischaemic attack or stroke. The study started in January 1991 and
is expected to be completed by December 1994. Nine hundred and fifty pa-
tients entered the trial and were treated for 12 months. The primary outcome
events were: non-fatal stroke (including cerebral haemorrhage), systemic
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